ROCKVILLE, Md., Oct. 16, 2024 (Globe Newswire) — Based on a new research report published by Fact.MR. Global orally disintegrating tablet market ready to reach the valuation of 24.45 billion USD In 2024, it will grow even further. 11.5% Aftertaste and mouthfeel are two areas of focus that suppliers are actively working on. The market is likely to evolve further in the coming years as more people seek tablets that are less bitter and run faster.
Orally disintegrating tablets (ODT) have a pleasant mouthfeel and are popular with a wide range of patients. These tablets do not require additional liquid to swallow, making them suitable for use anytime, anywhere. The introduction of orally disintegrating tablets can effectively address the challenges of swallowing traditional medicines, especially for infants, young children and the elderly.
To improve tablet performance and desirability, ongoing developments in this field have introduced a variety of orally disintegrating tablets with improved properties such as better taste and faster disintegration. These advances are important drivers of the increasing adoption of orally disintegrating tablets, which are gaining attention in the pharmaceutical industry.
To learn more about the market, request a sample of this report.https://www.factmr.com/connectus/sample?flag=S&rep_id=10142
Key points from market research:
- The valuation of the global orally disintegrating tablet market is: 72.68 billion USD By the end of 2034.
- The North American market is calculated to expand at a CAGR. 4% From 2024 to 2034.
- Analysis shows that the United States has a significant share. 5% in the North American region by the end of 2034.
- The Chilean market is expected to expand at a CAGR. 9% From 2024 to 2034.
- Based on drug class, the demand for anxiolytics is calculated to increase at a CAGR. 5% From 2024 to 2034.
“ODT is easy to administer and promotes patient adherence to treatment regimens compared to traditional tablets. Companies are focusing on improving the taste and mouthfeel of ODT to ensure increased patient adoption. ” Analysts at Fact.MR say:
Key companies driving innovation in the orally disintegrating tablet market:
Johnson & Johnson Services, Inc.; Teva Pharmaceutical Industries, Inc.; Sun Pharmaceutical Industries, Inc.; Takeda Pharmaceutical Company, Ltd.; Eli Lilly and Company. Dr. Reddy’s Laboratories Ltd; Mylan, Nevada; Bausch Health; GlaxoSmithKline; Merck & Company; AstraZeneca; Bayer AG; F. Hoffmann La Roche, Inc.
High level of patient compliance to ODT:
Orally disintegrating tablets have established a niche among oral drug delivery systems due to the high levels of compliance achieved by patients, especially in the elderly and pediatric population. Patients with dysphagia, motion sickness, repeated vomiting, and mental disorders prefer these drugs because they are unable to swallow large amounts of water.
Drugs that are well absorbed through the oral mucosa or have fast-acting pharmacological effects can be formulated into these dosage forms. However, these dosage forms are closely associated with the need to have sufficient mechanical strength to withstand harsh handling, while at the same time disintegrating within seconds upon contact with saliva.
Orally disintegrating tablet industry news:
Orally disintegrating tablets (ODT) is a highly competitive business, with many established companies and up-and-comers competing for market share.
Research, development, and commercialization of ODT and other pharmaceutical products are carried out by companies.
The main tactics these companies employ to maintain and expand their market share include product innovation, joint ventures and alliances, mergers and acquisitions, and regional growth. Oral antivirals and oral solid dosage contracts are two emerging industry trends that major competitors in the orally disintegrating tablet market are adapting to.
Customize this report for your specific research solution –https://www.factmr.com/connectus/sample?flag=S&rep_id=10142
Further valuable insights are provided:
Fact.MR, a new service, presents an unbiased analysis of the Orally Disintegrating Tablets market from 2019 to 2023 and forecast statistics from 2024 to 2034.
The study was based on drug class (antipsychotics, antiepileptics, central nervous system stimulants, anxiolytics, antiparkinsonian drugs, antihypertensives, NSAIDs, antiallergic drugs, proton pump inhibitors, and others), disease and uncover key market insights. Indications (CNS diseases, GI diseases, CVS diseases, allergies, etc.), distribution channels (hospital pharmacies, retail pharmacies, drug stores, online pharmacies), Europe across 7 major regions of the world (North America, Latin America, Eastern Europe, Western) , East Asia, South Asia and the Pacific, MEA).
Check out more related studies published by Fact.MR Research:
global Achalasia treatment market It is currently valued at approximately USD 472.12 million in 2024 and is expected to grow at a CAGR of 9.1% to reach USD 1.13 billion by the end of 2034.
global prosthetic eye market It is estimated that the valuation will reach USD 2.3 billion in 2024 and further expand at a CAGR of 8.7%, ultimately reaching USD 5.27 billion by 2034.
global Electromagnetic navigation bronchoscope market It is valued at USD 124.35 million in 2024 and is projected to grow at a CAGR of 8.9% to reach USD 292.77 million by 2034.
global Endoscopic balloon dilator market has been thoroughly analyzed to generate revenue worth USD 804.52 million in 2024, growing at a CAGR of 9.2% and reaching USD 1.94 billion by the end of 2034.
global Wax removal aid market The market is projected to grow at a CAGR of 5.8% to reach USD 386.32 million by the end of 2034.
About us:
Fact MR is a prominent market research firm known for its comprehensive market reports and valuable business insights. As a prominent player in business intelligence, we provide in-depth analysis to uncover market trends, growth paths, and competitive landscape. Known for our commitment to accuracy and reliability, we provide businesses with critical data and strategic recommendations to facilitate informed decision-making and strengthen their market positioning. With an unwavering dedication to providing trusted market intelligence, FACT.MR continues to help businesses confidently meet dynamic market challenges and achieve long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures our clients gain actionable insights to take advantage of new opportunities and gain an advantage in the competitive environment.
contact:
US office:
11140 Rockville Pike
suite 400
Rockville, MD 20852
US
Phone: +1 (628) 251-1583
sales team: sales@factmr.com
Follow us:LinkedIn | Twitter | Blog
